PCM4EU and PRIME-ROSE: Collaboration for implementation of precision cancer medicine in Europe
DOI:
https://doi.org/10.2340/1651-226X.2024.34791Keywords:
DRUP-like clinical trials, targeted drugs, reimbursement, public-private collaboration, synthetic control arms, molecular tumour boards, implementationAbstract
Background: In the two European Union (EU)-funded projects, PCM4EU (Personalized Cancer Medicine for all EU citizens) and PRIME-ROSE (Precision Cancer Medicine Repurposing System Using Pragmatic Clinical Trials), we aim to facilitate implementation of precision cancer medicine (PCM) in Europe by leveraging the experience from ongoing national initiatives that have already been particularly successful.
Patients and methods: PCM4EU and PRIME-ROSE gather 17 and 24 partners, respectively, from 19 European countries. The projects are based on a network of Drug Rediscovery Protocol (DRUP)-like clinical trials that are currently ongoing or soon to start in 11 different countries, and with more trials expected to be established soon. The main aims of both the projects are to improve implementation pathways from molecular diagnostics to treatment, and reimbursement of diagnostics and tumour-tailored therapies to provide examples of best practices for PCM in Europe.
Results: PCM4EU and PRIME-ROSE were launched in January and July 2023, respectively. Educational materials, including a podcast series, are already available from the PCM4EU website (http://www.pcm4eu.eu). The first reports, including an overview of requirements for the reimbursement systems in participating countries and a guide on patient involvement, are expected to be published in 2024.
Conclusion: European collaboration can facilitate the implementation of PCM and thereby provide affordable and equitable access to precision diagnostics and matched therapies for more patients.
Downloads
References
Hoes LR, van Berge Henegouwen JM, van der Wijngaart H, Zeverijn LJ, van der Velden DL, van de Haar J et al. Patients with rare cancers in the Drug Rediscovery Protocol (DRUP) benefit from genomics-guided treatment. Clin Cancer Res. 2022 Apr 1;28(7):1402–1411.
https://doi.org/10.1158/1078-0432.CCR-21-3752 DOI: https://doi.org/10.1158/1078-0432.CCR-21-3752
Andre F, Filleron T, Kamal M, Mosele F, Arnedos M, Dalenc F et al. Genomics to select treatment for patients with metastatic breast cancer. Nature. 2022 Oct;610(7931):343–348.
https://doi.org/10.1038/s41586-022-05068-3 DOI: https://doi.org/10.1038/s41586-022-05068-3
Leary A, Besse B, André F. The need for pragmatic, affordable, and practice-changing real-life clinical trials in oncology. Lancet. 2023;403(10424):406-408.
https://doi.org/10.1016/S0140-6736(23)02199-2 DOI: https://doi.org/10.1016/S0140-6736(23)02199-2
van der Velden DL, Hoes LR, van der Wijngaart H, van Berge Henegouwen JM, van Werkho-ven E, Roepman P et al. The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs. Nature. 2019;574(7776):127–131.
https://doi.org/10.1038/s41586-019-1600-x DOI: https://doi.org/10.1038/s41586-019-1600-x
Helland Å, Russnes HG, Fagereng GL, Al-Shibli K, Andersson Y, Berg T et al. Improving public cancer care by implementing precision medicine in Norway: IM-PRESS-Norway. J Transl Med. 2022;20(1): 317. https://doi.org/10.1186/s12967-022-03432-5 DOI: https://doi.org/10.1186/s12967-022-03432-5
Kringelbach T, Højgaard M, Rohrberg K, Spanggaard I, Laursen BE, Ladekarl M et al. ProTarget: a Danish Nationwide Clinical Trial on Targeted Cancer Treat-ment based on genomic profiling – a national, phase 2, prospective, multi-drug, non-randomized, open-label basket trial. BMC Cancer. 2023 Feb 22;23(1):182.
https://doi.org/10.1186/s12885-023-10632-9 DOI: https://doi.org/10.1186/s12885-023-10632-9
Mangat PK, Halabi S, Bruinooge SS, Garrett-Mayer E, Alva A, Janeway KA et al. Rationale and design of the Targeted Agent and Profiling Utilization Registry (TA-PUR) Study. JCO Precis Oncol. 2018;2018:10.1200.
https://doi.org/10.1200/PO.18.00122 DOI: https://doi.org/10.1200/PO.18.00122
Skamene T, Siu L, Renouf D, Laskin J, Bedard P, Jones S et al. Canadian profiling and tar-geted agent utilisation trial (CAPTUR/PM.1): a phase II basket precision medicine trial. J Clin Oncol. 2018:36(15-suppl): TPS12127.
https://doi.org/10.1200/JCO.2018.36.15_suppl.TPS12127 DOI: https://doi.org/10.1200/JCO.2018.36.15_suppl.TPS12127
Zeverijn LJ, Looze EJ, Thavaneswaran S, van Berge Henegouwen JM, Simes RJ, Hoes LR et al. Limited clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with cyclin D-CDK4/6 pathway alterations in the Dutch DRUP and Australian MoST trials. Int J Cancer. 2023 Oct 1;153(7):1413–1422.
https://doi.org/10.1200/JCO.2023.41.16_suppl.3101 DOI: https://doi.org/10.1200/JCO.2023.41.16_suppl.3101
van der Wijngaart H, Hoes LR, van Berge Henegouwen JM, van der Velden DL, Zeverijn LJ, Roepman P et al. Patients with Biallelic BRCA1/2 inactivation respond to olaparib treatment across histologic tumor types. Clin Cancer Res. 2021;27(22):6106–6114.
https://doi.org/10.1158/1078-0432.CCR-21-1104 DOI: https://doi.org/10.1158/1078-0432.CCR-21-1104
van Waalwijk van Doorn-Khosrovani SB, Pisters-van Roy A, van Saase L, van der Graaff M, Gijzen J, Sleijfer S et al. Personalised reimbursement: a risk-sharing model for biomarker-driven treatment of rare subgroups of cancer pa-tients. Ann Oncol. 2019;30(5):663–665.
https://doi.org/10.1093/annonc/mdz119 DOI: https://doi.org/10.1093/annonc/mdz119
Rosenquist R, Edsjö A, Russnes H, Lethiö J, Tamborero D, Hovig E et al. High-throughput molecular assays for inclusion in personalised oncology trials – state-of-the-art and beyond. J Intern Med. 2024 Jun;295(6):785-803.
https://doi.org/10.1111/joim.13785 DOI: https://doi.org/10.1111/joim.13785
Mateo J, Chakravarty D, Dienstmann R, Jezdic S, Gonzalez-Perez A, Lopez-Bigas N et al. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Tar-gets (ESCAT). Ann Oncol. 2018 Sep 1;29(9):1895–1902.
https://doi.org/10.1093/annonc/mdy263 DOI: https://doi.org/10.1093/annonc/mdy263
Zeverijn LJ, van Waalwijk van Doorn-Khosrovani SB, van Roy AAMGP, Timmers L, Ly Tran TH, de Boer JE et al. Harmonising patient-access programmes: the Dutch DRUG Access Protocol platform. Lancet Oncol. 2022 Feb;23(2):198–201.
https://doi.org/10.1016/S1470-2045(21)00707-5 DOI: https://doi.org/10.1016/S1470-2045(21)00707-5
Taskén K, Russnes HEG, Aas E, Bjørge L, Blix ES; CONNECT Public–Private Partnership Consortium et al. A national precision cancer medicine implementat-ion initiative for Norway. Nat Med. 2022 May;28(5):885–887.
Steen K, van Bueren E. Urban living labs: a living lab way of working. 2017: pp1-96. (publ Amsterdam Institute for Advanced Metropolitan Solutions and Delft University of Technology, Amsterdam, The Netherlands) https://www.ams-institute.org/documents/28/AMS_Living_Lab_Way_of_Working-ed4.pdf
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2023 Kjetil Taskén , Soemeya F. Haj Mohammad, Gro Live Fagereng, Ragnhild Sørum Falk, Åslaug Helland, Sahar Barjesteh van Waalwijk van Doorn-Khosrovani, Katarina Steen Carlsson, Bettina Ryll, Katriina Jalkanen, Anders Edsjö, Hege G. Russnes, Ulrik Lassen, Ebba Hallersjö Hult, Iwona Lugowska, Jean-Yves Blay, Loic Verlingue, Edvard Abel, Maeve A. Lowery, Matthew G. Krebs, Kristoffer Staal Rohrberg, Kristiina Ojamaa, Julio Oliveira, Henk M.W. Verheul, Emile E. Voest, Hans Gelderblom
This work is licensed under a Creative Commons Attribution 4.0 International License.
